Unknown PHASE2 INTERVENTIONAL 2-arm NCT04854928

Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.

A Double-blind, Placebo-controlled, Interventional Parallel Group Study to Evaluate the Antiviral Effect of a Single Nasal Application of LTX-109 3% Gel, in Comparison to Placebo Gel, in Subjects With COVID-19 Infection.

Sponsor: CTC Clinical Trial Consultants AB

Conditions COVID-19

Interventions LTX-109 gel, 3% Placebo gel

Updated 5 times since 2021 Last updated: Sep 17, 2021 Started: May 3, 2021 Primary completion: Feb 28, 2022 Completion: May 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on COVID-19, this trial is ongoing. The trial is conducted by CTC Clinical Trial Consultants AB and has accumulated 5 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
May 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Oct 2021 — May 2023 [monthly]

Recruiting PHASE2
May 2021 — Oct 2021 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CTC Clinical Trial Consultants AB
Pharma Holdings AS

Data source: Pharma Holdings AS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Uppsala, Sweden